Clinicopathologic Features and Survival Outcomes of Secondary Mantle Cell Lymphoma after Primary Solid Malignancy

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2652-2652
Author(s):  
Raji Shameem ◽  
Muhammad Saad Hamid ◽  
Nasheed Mohammad Hossain ◽  
Jeffrey Mufson ◽  
Patricia L. Kropf
Keyword(s):  
Mantle Cell Lymphoma ◽  
Head And Neck ◽  
De Novo ◽  
Cell Lymphoma ◽  
Latency Period ◽  
Stage Iv ◽  
Nodal Involvement ◽  
Solid Malignancy ◽  
Mantle Cell ◽  
Race Ethnicity

Abstract Background: Mantle Cell Lymphoma (MCL) is a rare sub-type of Non-Hodgkin's Lymphoma (NHL). Outcomes of secondary MCL (sMCL) in patients with a prior diagnosis of a solid malignancy as compared to de novo MCL are not well understood. Differences may be attributable to age, gender, race/ethnicity, extra-nodal involvement, and stage at initial diagnosis. We sought to determine differences in outcome by analyzing data from a large nationwide cancer registry. Methods: The Surveillance Epidemiology and End Results (SEER) database (1973-2012) was used to detect MCL (ICD-O-3 code: 9673/3) adult (>18 years) cases. The variable "First Malignant Primary Indicator" was used to differentiate between de novo and sMCL cases. Primary solid malignancy subtypes categorized included prostate, breast, colorectal, lung bladder, renal, head and neck, thyroid, testicular, and endometrial cancer. Selected sMCL cases included patients with a diagnosis of a primary solid malignancy with a latency period ≥ 2 months. Overall survival (OS) was calculated using the cox regression model to determine the impact of sMCL on survival, adjusting for age at diagnosis, race/ethnicity, primary solid malignancy subtype type and latency period. Chi square test was utilized to ascertain for any significant difference between de novo MCL and sMCL cases. Results: Overall, 8,889 patients were included: 875 (9.8%) sMCL and 8,014 (90.2%) de novo MCL cases. For de novo MCL, 67.1% were males. Race/ethnicity in descending frequency consisted of Non-Hispanic Whites (NHW) (81.8%), Hispanics (8.4%), Blacks (4.4%), Asian and Pacific Islanders(API)(4.1%) and American Indian/Native Indian (AI) (0.4%). The most frequent stage at initial diagnosis for de novo MCL was stage IV (57.9%) followed by stage III (13.4%), stage II (8.1%) and stage I (10.0%). Males consisted of 75.4% of sMCL cases. Cases of sMCL categorized by race/ethnicity in descending frequency were NHW (87.3%), Hispanics (5.1%), Blacks (4.2%), API (3.2%) and AI (0.1%). Stage at diagnosis for sMCL was most frequently stage IV (54.6%), followed by stage III (15.8%), stage II (10.9%) and stage I (11.7%). Compared to de novo MCL, sMCL cases were more likely to occur in patient's ≥75 years (48.3% vs. 28.7%, p<0.01). An absence of extra-nodal involvement at diagnosis was common in both de novo MCL (84.0%) and sMCL (83.7%). Specific to sMCL cases, more than 90% of primary solid malignancies were limited to local/regional involvement. All primary solid malignancy subtypes except for head and neck (48 months) and renal cancer (59 months) had a latency period of greater 5 years. Median OS was significantly worse in sMCL (34 months) compared to de novo MCL (53 months) (HR: 1.375, 95% CI:1.243-1.504). Conclusion: Our analysis demonstrates that elderly age appears to be significantly more common in sMCL cases as compared to de novo MCL. By contrast, race/ethnicity, and extra-nodal involvement were similar between the two groups. Survival was worse in sMCL compared to de novo MCL. This may be due to differences in treatment preferences. Further studies are necessary to elucidate the etiology for such differences in outcomes. Disclosures Kropf: Teva Pharmaceuticals: Consultancy.

Mantle Cell Lymphoma: Combined Extranodal/Nodal Involvement of The Head And Neck With Multifocal Oral Manifestation

2014 ◽  
Vol 117 (2) ◽  
pp. e127
Author(s):  
MIRNA SCALON CORDEIRO ◽  
GILBERTO MARCUCCI ◽  
MARCELO MARCUCCI ◽  
KARINA CECÍLIA PANELLI SANTOS ◽  
LUIZA VERÔNICA WARMLING ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Head And Neck ◽  
Cell Lymphoma ◽  
Nodal Involvement ◽  
Oral Manifestation ◽  
Mantle Cell

Mantle cell lymphoma: a rare cause for a swollen palate

2020 ◽  
Vol 13 (10) ◽  
pp. e238332
Author(s):  
Ayah Mohamed ◽  
Rachel Cowie ◽  
Dáire Shanahan
Keyword(s):  
Mantle Cell Lymphoma ◽  
Hard Palate ◽  
Cell Lymphoma ◽  
Stage Iv ◽  
Accurate Diagnosis ◽  
The Body ◽  
Oral Medicine ◽  
Medicine Department ◽  
Mantle Cell ◽  
Dental Hospital

We describe the case of a 68-year-old woman who was referred to the Oral Medicine Department in the Bristol Dental Hospital in November 2018 regarding a mass in the hard palate. The patient was previously diagnosed with stage IV mantle cell lymphoma of the upper tarsal conjunctiva in December 2014. Further investigations revealed lymphomatous deposits in other sites throughout the body. This patient underwent six cycles of chemotherapy, followed by consolidation LACE autograph and maintenance rituximab. While mantle cell lymphoma very rarely presents on the hard palate, knowledge of its clinical features and differential diagnoses is imperative in its accurate diagnosis and appropriate management.

scholarly journals Mantle cell lymphoma relapsing at the lymphedematous arm.

2013 ◽  
Vol 5 (1) ◽  
pp. e2013016 ◽  
Author(s):  
Giuseppina Massini ◽  
Stefan Hohaus ◽  
Francesco D'Alo' ◽  
Valentina Bozzoli ◽  
Barbara Vannata ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Negative Impact ◽  
Medical Condition ◽  
Stage Iv ◽  
Chronic Medical Condition ◽  
Interstitial Tissue ◽  
Cancer Treatments ◽  
Mantle Cell ◽  
Long Term Survivors

Lymphedema (LE) is a chronic medical condition characterized by lymphatic fluid retention, resulting in tissue swelling. Cancer treatments involving lymph nodes can damage lymph drainage routes, causing accumulation of lymph fluid in the interstitial tissue of related limbs and body areas and secondary LE.  Basically, the LE has a negative impact on physical and mental quality of life. Moreover, 0.07-0.04% of long term survivors (most patients undergone mastectomy) can develop the Stewart-Treves syndrome,  a rare and aggressive multifocal lymphangiosarcoma arising within the LE region. Here we describe a   45-year-old woman  with a massive LE of the left arm,  as a consequence of previous breast cancer,  who  was diagnosed after 4 years  of stage IV mantle cell lymphoma (MCL) . The patient after obtaining complete remission with chemotherapy and ABMT  relapsed of MCL in lymphedema site.

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4942-4942
Author(s):  
Ana García-Noblejas ◽  
Belén Navarro Matilla ◽  
Carolina Da Silva Rodriguez ◽  
Raquel De Oña Navarrete ◽  
María José Ramirez Sánchez ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Mantle Cell Lymphoma ◽  
Retrospective Analysis ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
Alkylating Agents ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Median Number ◽  
Mantle Cell

Abstract Abstract 4942 INTRODUCTION. Patients with Mantle cell lymphoma (MCL) have an adverse outcome after relapse due to chemorefractory disease with conventional treatments. Bendamustine, a nitrogen mustard compound chemically related to the alkylating agents, has demonstrated high efficacy with a low toxicity profile in reported clinical trials. AIM. To analyze the Spanish experience in patients with relapsed/refractory MCL treated with Bendamustine. METHODS. Retrospective analysis of spanish experience in relapsed/refractory MCL treated with Bendamustine alone or in combination. This study has been approved by local ethical committees. RESULTS. Currently, there are 36 patients registered and 28 are available for this analysis. Patients'characteristics: 69% male, median age 65 years old (range 41–81), 87% ECOG≤ 1, 83% Ann Arbor stage IV, 37% high risk MIPI and 9% blastic variant. Previous regimens were CHOP or CHOP like ± R in 42.5%, HyperCVAD/MtxAraC ± R in 42.5%, R-CVP in 9% and other regimens in 6%. Median number of previous treatments were 2.6 (range 1–6), all patients had received prior Rituximab and 73% had chemosensitive disease to the last treatment. Bendamustine regimen was R-B (R-375mg/m2 D1, B-90 mg/m2 D1-2) in 78% patients, R-B with B-70 mg/m2 in 8%, B alone in 3%, R-B-Bortezomib in 3% and R-B plus consolidation (SCT, Y90Ibritumomab-tiuxetan) in 8%. Median number of cycles was 4.61 (range 1–7). G- CSF support was administered in 43% of cycles. Response: Overall response rate was 73%, with 43% CR & uCR and 30% PR. Survival: Median overall survival from diagnosis is 8,26 years (range: 1.6–11,6 years) without plateau. Median progression free survival (PFS) after Bendamustine treatment was 16 months (95% CI: 11.7–20.4), data that compares favourably with patients' PFS to previous therapy (12 months, 95% CI: 6.5–17.5). Median PFS for patients who achieved CR/uCR is 32.6 months (95% CI: 19.9–45.4) versus 11 months in patients with PR (95% CI: 3.9–18.8). With a median follow-up for surviving patients of 12 months since Bendamustine treatment, the estimated OS at 3 years is 47% (+ SD 14%). Toxicity: No treatment related mortality has been described so far. Over 152 cycles, only 10 hospitalizations due to febrile neutropenia were reported. No one case of lysis tumoral syndrome has been reported. CONCLUSION. Bendamustine plus Rituximab is a good rescue treatment in non selected pretreated patients with mantle cell lymphoma. CR rate and duration of response seem to reproduce in current clinical practice the good data reported in previous clinical trials and compares favourably with other available treatments. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Diagnosis of Therapy-related Acute Myeloid Leukemia with t(8;21)(q22;q22.1) after Treatment for Mantle Cell Lymphoma and Oral Squamous Cell Carcinoma

2019 ◽  
pp. 1-7
Author(s):  
Patrícia Colombo Corrêa ◽  
Íris Mattos Santos-Pirath ◽  
Chandra Chiappin Cardoso ◽  
Camila Mattiolo ◽  
Bruno Vieira Dias ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mantle Cell Lymphoma ◽  
Squamous Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Correct Diagnosis ◽  
Treatment Strategies ◽  
Mantle Cell

Aims: We report a rare case of therapy-related AML with t(8;21)(q22;q22.1) that occurred after treatment for mantle cell lymphoma (MCL) and oral squamous cell carcinoma (OSCC). Presentation of Case: A 52 years-old male patient was diagnosed with MCL in leukemic phase. The treatment consisted in R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, then patient experienced remission. Three months later, he presented a lump that was diagnosed as OSCC, which was surgically removed and treated with cisplatin and radiotherapy. Then, the patient’s hemogram presented 35.0% of blasts and, after morphologic, phenotypic and molecular analysis, it was classified as AML with t(8;21)(q22;q22.1). However, due to the previous historic of chemotherapy and radiotherapy, the final diagnosis was t-AML. Discussion: The correct diagnosis of therapy related malignancies is important due to its severity as they are very aggressive and, usually, considered incurable. t-AMLs with t(8;21)(q22;q22.1) is considered as favorable karyotype, still, it has a poorer outcome compared with its de novo counterpart. Conclusion: t-AML with t(8;21)(q22;q22.1) is rare and few cases are described in the literature. More reports are necessary to better elucidate the mechanisms involved in this disease to define better treatment strategies to prevent these events and to improve the poor outcomes.

A Multicentre Phase II Trial Testing Gemcitabine in the Treatment of Patients with Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma: SAKK 36/03.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4454-4454
Author(s):  
Felicitas Hitz ◽  
Giovanni Martinelli ◽  
Emanuele Zucca ◽  
Walter Mingrone ◽  
Roger Von Moos ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Treatment Failure ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Stage Iv ◽  
Response Duration ◽  
Intensive Chemotherapy ◽  
Newly Diagnosed ◽  
Mantle Cell ◽  
Trial Treatment

Abstract Mantle cell lymphoma (MCL) has a very poor prognosis. Remissions are often incomplete and short with a median survival of less than 3 years and a 5 year survival of < 30%. Young patients are usually treated with intensive chemotherapy regimens or a stem cell transplant. In elderly, unfit patients aggressive treatments are not a realistic approach. This trial set out to assess Gemcitabine in the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant MCL not fit enough for intensive chemotherapy regimens. The primary endpoint was the objective response. Eligibility criteria were a WHO performance status < 2, age ≥ 18 years, a histologically confirmed diagnosis of MCL along with at least one measurable lesion of diameter ≥ 11 mm, ≤ 2 previous lines of chemotherapy. Gemcitabine was given in doses of 1000mg/m2 as a 30 minute infusion on days 1 and 8 of each 3 week cycle for a total of 9 cycles. To prevent flu-like symptoms, one dose of steroids per Gemcitabine infusion was administered. Response duration was read as the time from trial registration to a relapse for patients reaching a remission on the trial therapy. Progression-free survival was defined as the time from trial registration to death or disease progression, treatment failure as early termination of the trial treatment. Patient enrollment began in Aug 2004. Stage I analysis concluded the trial treatment was not promising for further investigation, due to only 1 (10%) patient reaching a remission, and patient accrual stopped after the inclusion of 18 patients in March 2006. Median age at enrollment was 70 years. 66% of the patients were male. MCL was newly diagnosed in 50% of the patients and relapsed in the remainder. Ann Arbor stage IV rating was present in 15 patients, stage II in 1 patient and stage I in 2 patients. Bone marrow involvement was reported in 10 patients. Gastrointestinal tract involvement was reported in 4 patients. Involvement of > 1 extranodal organ was seen in 3 patients. One CR, 4 PRs, 8 SDs and 4 PDs were recorded as a best response. The patient achieving a CR was one of the patients presenting with a stage IV disease. Most myelotoxicities occurred during the first chemotherapy cycle. Neutropenia CTC grade 1 in 24 (19.8%), grade 2 in 35 (28.9%) and grade 3/4 was seen in 24 (19.8%) of the cycles. Thrombocytopenia CTC grade 1 was recorded in 55 (45.5%) cycles and grade 2/3 in 9 (7.7%) cycles. Three patients developed non-hematological serious adverse events, defined as an inpatient or prolonged hospitalisation or a life threatening illness related to the trial medication; dyspnea, glomerular microangiopathy with hemolytic uremic syndrome, and hyperglycemia. The median time-to-progression and response duration was 8.0 (95% confidence interval: 5.5 – 9.3) and 10.6 (95% confidence interval: 5.5 – 10.9) months respectively. The median time-to-treatment failure was not reached. We conclude that Gemcitabine is well tolerated and that it can stabilise MCL in elderly patients. However, Gemcitabine as a monotherapy has only limited activity in MCL patients in terms of treatment response. Further trials should therefore assess gemcitabine in frail patients with MCL.

Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma

2015 ◽  
Vol 76 (1) ◽  
pp. 211-216 ◽  
Author(s):  
John M. Burke ◽  
Richard H. C. van der Jagt ◽  
Ian W. Flinn ◽  
Michael D. Craig ◽  
Ling Chen ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Qt Interval ◽  
De Novo ◽  
Cell Lymphoma ◽  
Interval Duration ◽  
Mantle Cell ◽  
Qt Interval Duration

Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes

2003 ◽  
Vol 34 (10) ◽  
pp. 1030-1034 ◽  
Author(s):  
Laurentia Nodit ◽  
David W Bahler ◽  
Samuel A Jacobs ◽  
Joseph Locker ◽  
Steven H Swerdlow
Keyword(s):  
Mantle Cell Lymphoma ◽  
Heavy Chain ◽  
Cell Lymphoma ◽  
Immunoglobulin Heavy Chain ◽  
Nodal Involvement ◽  
Mantle Cell ◽  
Immunoglobulin Heavy Chain Genes

Current Treatment Approaches for Mantle-Cell Lymphoma

2005 ◽  
Vol 23 (26) ◽  
pp. 6409-6414 ◽  
Author(s):  
Thomas E. Witzig
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Stage Iv ◽  
Current Treatment ◽  
New Agents ◽  
Male Predominance ◽  
Response To Chemotherapy ◽  
Mantle Cell ◽  
Stage Iv Disease

Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The cells are characterized as CD20+ CD5+ CD23− with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. Response to chemotherapy usually results in a tumor response but unmaintained remissions are short and the median survival is 3 to 4 years. The treatment approach to newly diagnosed patients with MCL depends on the patient's eligibility for stem cell transplantation (SCT). Those who are eligible are usually treated with either rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by SCT or rituximab-HyperCVAD (cyclophosphamide, vincristine, doxorubicin, decadron, cytarabine, and methotrexate) followed by observation. The purine nucleoside analogues also have activity as single agents and with rituximab. Unfortunately none of these approaches can definitively cure patients with MCL, and new agents are needed. Recent studies in patients with relapsed MCL have shown substantial antitumor activity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rituximab. Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity.

Sign in / Sign up

Export Citation Format

Share Document